Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharnext
Biotech
Pharnext blames ‘unexpected’ placebo results for phase 3 failure
Less than a year after Pharnext dropped its Alzheimer’s work, the biotech has seen its lead program fail a trial in a rare neurological disease.
James Waldron
Dec 11, 2023 9:18am
Pharnext ditches Alzheimer's plans to save cash
Feb 14, 2023 11:01am
Acorda CMO hits the exit, landing Pharnext job
Nov 24, 2021 7:10am
Pharnext muscle wasting phase 3 hits primary endpoint
Oct 17, 2018 8:49am
EuroBiotech: More Articles of Note
May 11, 2017 9:19am
EuroBiotech Report—Cell Medica, Astex, Galapagos and more
Mar 16, 2017 9:43am
